Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.

Tintelnot J, Baum N, Schultheiß C, Braig F, Trentmann M, Finter J, Fumey W, Bannas P, Fehse B, Riecken K, Schuetze K, Bokemeyer C, Rösner T, Valerius T, Peipp M, Koch-Nolte F, Binder M.

Mol Cancer Ther. 2019 Apr;18(4):823-833. doi: 10.1158/1535-7163.MCT-18-0849. Epub 2019 Mar 1.

PMID:
30824613
2.

FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils.

Treffers LW, van Houdt M, Bruggeman CW, Heineke MH, Zhao XW, van der Heijden J, Nagelkerke SQ, Verkuijlen PJJH, Geissler J, Lissenberg-Thunnissen S, Valerius T, Peipp M, Franke K, van Bruggen R, Kuijpers TW, van Egmond M, Vidarsson G, Matlung HL, van den Berg TK.

Front Immunol. 2019 Jan 30;9:3124. doi: 10.3389/fimmu.2018.03124. eCollection 2018.

3.

Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia.

Kellner C, Peipp M, Gramatzki M, Schrappe M, Schewe DM.

Oncoimmunology. 2018 Apr 9;7(8):e1448331. doi: 10.1080/2162402X.2018.1448331. eCollection 2018.

4.

Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity.

Kellner C, Derer S, Klausz K, Rosskopf S, Wirt T, Rösner T, Otte A, Cappuzzello E, Peipp M.

Methods Mol Biol. 2018;1827:381-397. doi: 10.1007/978-1-4939-8648-4_20.

PMID:
30196508
5.

Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells.

Oberg HH, Kellner C, Gonnermann D, Sebens S, Bauerschlag D, Gramatzki M, Kabelitz D, Peipp M, Wesch D.

Front Immunol. 2018 Apr 19;9:814. doi: 10.3389/fimmu.2018.00814. eCollection 2018.

6.

A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries.

Klausz K, Cieker M, Kellner C, Oberg HH, Kabelitz D, Valerius T, Burger R, Gramatzki M, Peipp M.

Oncotarget. 2017 Sep 5;8(44):77552-77566. doi: 10.18632/oncotarget.20641. eCollection 2017 Sep 29.

7.

Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy.

Kellner C, Otte A, Cappuzzello E, Klausz K, Peipp M.

Transfus Med Hemother. 2017 Sep;44(5):327-336. doi: 10.1159/000479980. Epub 2017 Sep 8. Review.

8.

An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity.

Wirt T, Rosskopf S, Rösner T, Eichholz KM, Kahrs A, Lutz S, Kretschmer A, Valerius T, Klausz K, Otte A, Gramatzki M, Peipp M, Kellner C.

Transfus Med Hemother. 2017 Sep;44(5):292-300. doi: 10.1159/000479978. Epub 2017 Sep 11.

9.

Antibody Engineering - Tailor-Made Next Generation Antibodies by Molecular Design.

Humpe A, Peipp M.

Transfus Med Hemother. 2017 Sep;44(5):290-291. doi: 10.1159/000479617. Epub 2017 Sep 13. No abstract available.

10.

CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.

Peipp M, Wesch D, Oberg HH, Lutz S, Muskulus A, van de Winkel JGJ, Parren PWHI, Burger R, Humpe A, Kabelitz D, Gramatzki M, Kellner C.

Scand J Immunol. 2017 Oct;86(4):196-206. doi: 10.1111/sji.12581.

11.

An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts.

Schewe DM, Alsadeq A, Sattler C, Lenk L, Vogiatzi F, Cario G, Vieth S, Valerius T, Rosskopf S, Meyersieck F, Alten J, Schrappe M, Gramatzki M, Peipp M, Kellner C.

Blood. 2017 Sep 28;130(13):1543-1552. doi: 10.1182/blood-2017-01-764316. Epub 2017 Jul 11.

12.

Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.

Lohse S, Loew S, Kretschmer A, Jansen JHM, Meyer S, Ten Broeke T, Rösner T, Dechant M, Derer S, Klausz K, Kellner C, Schwanbeck R, French RR, Tipton TRW, Cragg MS, Schewe DM, Peipp M, Leusen JHW, Valerius T.

Br J Haematol. 2018 May;181(3):413-417. doi: 10.1111/bjh.14624. Epub 2017 Apr 27. No abstract available.

PMID:
28449349
13.

Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth.

Burger R, Günther A, Klausz K, Staudinger M, Peipp M, Penas EM, Rose-John S, Wijdenes J, Gramatzki M.

Haematologica. 2017 Feb;102(2):381-390. doi: 10.3324/haematol.2016.145060. Epub 2016 Sep 22.

14.

Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients.

Oberg HH, Grage-Griebenow E, Adam-Klages S, Jerg E, Peipp M, Kellner C, Petrick D, Gonnermann D, Freitag-Wolf S, Röcken C, Sebens T, Vogel I, Becker T, Ebsen M, Kabelitz D, Wesch D, Sebens S.

Pancreatology. 2016 Nov - Dec;16(6):1069-1079. doi: 10.1016/j.pan.2016.07.008. Epub 2016 Jul 11.

PMID:
27424476
15.

Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.

Kellner C, Günther A, Humpe A, Repp R, Klausz K, Derer S, Valerius T, Ritgen M, Brüggemann M, van de Winkel JG, Parren PW, Kneba M, Gramatzki M, Peipp M.

Oncoimmunology. 2015 Jun 5;5(1):e1058459. eCollection 2016.

16.

An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo.

Lohse S, Meyer S, Meulenbroek LA, Jansen JH, Nederend M, Kretschmer A, Klausz K, Möginger U, Derer S, Rösner T, Kellner C, Schewe D, Sondermann P, Tiwari S, Kolarich D, Peipp M, Leusen JH, Valerius T.

Cancer Res. 2016 Jan 15;76(2):403-17. doi: 10.1158/0008-5472.CAN-15-1232. Epub 2015 Dec 3.

17.

A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells.

Derer S, Cossham M, Rösner T, Kellner C, Beurskens FJ, Schwanbeck R, Lohse S, Sina C, Peipp M, Valerius T.

J Immunol. 2015 Nov 15;195(10):5077-87. doi: 10.4049/jimmunol.1501458. Epub 2015 Oct 16.

18.

HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.

Peipp M, Derer S, Lohse S, Staudinger M, Klausz K, Valerius T, Gramatzki M, Kellner C.

Oncotarget. 2015 Oct 13;6(31):32075-88. doi: 10.18632/oncotarget.5135.

19.

Molecular Mechanisms by Which a Fucus vesiculosus Extract Mediates Cell Cycle Inhibition and Cell Death in Pancreatic Cancer Cells.

Geisen U, Zenthoefer M, Peipp M, Kerber J, Plenge J, Managò A, Fuhrmann M, Geyer R, Hennig S, Adam D, Piker L, Rimbach G, Kalthoff H.

Mar Drugs. 2015 Jul 20;13(7):4470-91. doi: 10.3390/md13074470.

20.

γδ T cell activation by bispecific antibodies.

Oberg HH, Kellner C, Gonnermann D, Peipp M, Peters C, Sebens S, Kabelitz D, Wesch D.

Cell Immunol. 2015 Jul;296(1):41-9. doi: 10.1016/j.cellimm.2015.04.009. Epub 2015 May 1.

PMID:
25979810
21.

Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity.

Gonnermann D, Oberg HH, Kellner C, Peipp M, Sebens S, Kabelitz D, Wesch D.

Oncoimmunology. 2015 Jan 7;4(3):e988460. eCollection 2015 Mar.

22.

The novel multispecies Fc-specific Pseudomonas exotoxin A fusion protein α-Fc-ETA' enables screening of antibodies for immunotoxin development.

Klausz K, Kellner C, Derer S, Valerius T, Staudinger M, Burger R, Gramatzki M, Peipp M.

J Immunol Methods. 2015 Mar;418:75-83. doi: 10.1016/j.jim.2015.02.002. Epub 2015 Feb 18.

PMID:
25701195
23.

Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy.

Oberg HH, Kellner C, Peipp M, Sebens S, Adam-Klages S, Gramatzki M, Kabelitz D, Wesch D.

Front Immunol. 2014 Dec 17;5:643. doi: 10.3389/fimmu.2014.00643. eCollection 2014. Review.

24.

Fc-optimized antibodies quickly pull the trigger.

Kellner C, Peipp M.

Blood. 2014 Nov 20;124(22):3180-1. doi: 10.1182/blood-2014-10-602219.

25.

Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loop.

Rösner T, Lohse S, Peipp M, Valerius T, Derer S.

J Immunol. 2014 Aug 1;193(3):1485-95. doi: 10.4049/jimmunol.1400329. Epub 2014 Jun 27.

26.

Complement in antibody-based tumor therapy.

Derer S, Beurskens FJ, Rosner T, Peipp M, Valerius T.

Crit Rev Immunol. 2014;34(3):199-214. Review.

PMID:
24941073
27.

The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.

Staudinger M, Glorius P, Burger R, Kellner C, Klausz K, Günther A, Repp R, Klapper W, Gramatzki M, Peipp M.

Blood Cancer J. 2014 Jun 13;4:e219. doi: 10.1038/bcj.2014.38.

28.

Fc engineering of antibodies and antibody derivatives by primary sequence alteration and their functional characterization.

Derer S, Kellner C, Rösner T, Klausz K, Glorius P, Valerius T, Peipp M.

Methods Mol Biol. 2014;1131:525-40. doi: 10.1007/978-1-62703-992-5_33.

PMID:
24515488
29.

Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody.

Brunke C, Lohse S, Derer S, Peipp M, Boross P, Kellner C, Beyer T, Dechant M, Royle L, Liew LP, Leusen JH, Valerius T.

MAbs. 2013 Nov-Dec;5(6):936-45. doi: 10.4161/mabs.26396.

30.

HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.

de Goeij BE, Peipp M, de Haij S, van den Brink EN, Kellner C, Riedl T, de Jong R, Vink T, Strumane K, Bleeker WK, Parren PW.

MAbs. 2014 Mar-Apr;6(2):392-402. doi: 10.4161/mabs.27705. Epub 2014 Jan 3.

31.

Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity.

Derer S, Glorius P, Schlaeth M, Lohse S, Klausz K, Muchhal U, Desjarlais JR, Humpe A, Valerius T, Peipp M.

MAbs. 2014 Mar-Apr;6(2):409-21. doi: 10.4161/mabs.27457. Epub 2013 Dec 11.

32.

Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells.

Oberg HH, Peipp M, Kellner C, Sebens S, Krause S, Petrick D, Adam-Klages S, Röcken C, Becker T, Vogel I, Weisner D, Freitag-Wolf S, Gramatzki M, Kabelitz D, Wesch D.

Cancer Res. 2014 Mar 1;74(5):1349-60. doi: 10.1158/0008-5472.CAN-13-0675. Epub 2014 Jan 21.

33.

Antibody-dependent cellular cytotoxicity in patients on chronic hemodialysis.

Koch T, Derer S, Staudinger M, Rossen K, Glorius P, Peipp M, Kellner C, Kunzendorf U, Valerius T, Dechant M.

Am J Nephrol. 2013;38(5):379-87. doi: 10.1159/000355972. Epub 2013 Oct 23.

PMID:
24157422
34.

IgA EGFR antibodies mediate tumour killing in vivo.

Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, van Rooijen N, Bleeker WK, Parren PW, van de Winkel JG, Valerius T, Leusen JH.

EMBO Mol Med. 2013 Aug;5(8):1213-26. doi: 10.1002/emmm.201201929.

35.

Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype.

Kellner C, Gramatzki M, Peipp M.

Oncoimmunology. 2013 Jun 1;2(6):e24481. Epub 2013 May 9.

36.

Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions.

Kellner C, Derer S, Valerius T, Peipp M.

Methods. 2014 Jan 1;65(1):105-13. doi: 10.1016/j.ymeth.2013.06.036. Epub 2013 Jul 9.

PMID:
23851282
37.

An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels.

Rösner T, Derer S, Kellner C, Dechant M, Lohse S, Vidarsson G, Peipp M, Valerius T.

Br J Haematol. 2013 Apr;161(2):282-6. doi: 10.1111/bjh.12209. Epub 2013 Jan 7. No abstract available.

PMID:
23294176
38.

The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients.

Kellner C, Zhukovsky EA, Pötzke A, Brüggemann M, Schrauder A, Schrappe M, Kneba M, Repp R, Humpe A, Gramatzki M, Peipp M.

Leukemia. 2013 Jul;27(7):1595-8. doi: 10.1038/leu.2012.373. Epub 2013 Jan 1. No abstract available.

PMID:
23277329
39.

Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies.

Derer S, Bauer P, Lohse S, Scheel AH, Berger S, Kellner C, Peipp M, Valerius T.

J Immunol. 2012 Dec 1;189(11):5230-9. doi: 10.4049/jimmunol.1202037. Epub 2012 Oct 24.

40.

Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.

Kellner C, Maurer T, Hallack D, Repp R, van de Winkel JG, Parren PW, Valerius T, Humpe A, Gramatzki M, Peipp M.

J Immunol. 2012 Nov 15;189(10):5037-46. doi: 10.4049/jimmunol.1201321. Epub 2012 Oct 12.

41.

ADAM17-overexpressing breast cancer cells selectively targeted by antibody-toxin conjugates.

Trad A, Hansen HP, Shomali M, Peipp M, Klausz K, Hedemann N, Yamamoto K, Mauermann A, Desel C, Lorenzen I, Lemke H, Rose-John S, Grötzinger J.

Cancer Immunol Immunother. 2013 Mar;62(3):411-21. doi: 10.1007/s00262-012-1346-x. Epub 2012 Sep 1.

PMID:
22940887
42.

Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function.

Derer S, Kellner C, Berger S, Valerius T, Peipp M.

Methods Mol Biol. 2012;907:519-36. doi: 10.1007/978-1-61779-974-7_30.

PMID:
22907372
43.

Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96.

Mohseni Nodehi S, Repp R, Kellner C, Bräutigam J, Staudinger M, Schub N, Peipp M, Gramatzki M, Humpe A.

PLoS One. 2012;7(8):e42426. doi: 10.1371/journal.pone.0042426. Epub 2012 Aug 3.

44.

Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.

Lohse S, Brunke C, Derer S, Peipp M, Boross P, Kellner C, Beyer T, Dechant M, van der Winkel JG, Leusen JH, Valerius T.

J Biol Chem. 2012 Jul 20;287(30):25139-50. doi: 10.1074/jbc.M112.353060. Epub 2012 Jun 7.

45.

The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells.

Glorius P, Baerenwaldt A, Kellner C, Staudinger M, Dechant M, Stauch M, Beurskens FJ, Parren PW, Winkel JG, Valerius T, Humpe A, Repp R, Gramatzki M, Nimmerjahn F, Peipp M.

Leukemia. 2013 Jan;27(1):190-201. doi: 10.1038/leu.2012.150. Epub 2012 Jun 4.

PMID:
22660187
46.

Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.

Derer S, Berger S, Schlaeth M, Schneider-Merck T, Klausz K, Lohse S, Overdijk MB, Dechant M, Kellner C, Nagelmeier I, Scheel AH, Lammerts van Bueren JJ, van de Winkel JG, Parren PW, Peipp M, Valerius T.

Neoplasia. 2012 Mar;14(3):190-205.

47.

Retraction for Lammerts van Bueren et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility.

Lammerts van Bueren JJ, Bleeker WK, Brännström A, Jansson M, Peipp M, Schneider-Merck T, Valerius T, van de Winkel JG, Parren PW.

Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5548. doi: 10.1073/pnas.1203736109. Epub 2012 Mar 19. No abstract available.

48.

Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity.

Kellner C, Hallack D, Glorius P, Staudinger M, Mohseni Nodehi S, de Weers M, van de Winkel JG, Parren PW, Stauch M, Valerius T, Repp R, Humpe A, Gramatzki M, Peipp M.

Leukemia. 2012 Apr;26(4):830-4. doi: 10.1038/leu.2011.288. Epub 2011 Oct 18. No abstract available.

PMID:
22005785
49.

Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.

Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PH, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M.

J Immunol Methods. 2011 Oct 28;373(1-2):67-78. doi: 10.1016/j.jim.2011.08.003. Epub 2011 Aug 9.

PMID:
21855548
50.

Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development.

Kellner C, Bleeker WK, Lammerts van Bueren JJ, Staudinger M, Klausz K, Derer S, Glorius P, Muskulus A, de Goeij BE, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M.

J Immunol Methods. 2011 Aug 31;371(1-2):122-33. doi: 10.1016/j.jim.2011.06.023. Epub 2011 Jun 30.

PMID:
21756911

Supplemental Content

Support Center